Recurrent Chest Pain with Normal Tests in Women: What It Means and What to Do

She has had three emergency department visits in the past year. Each time, the troponin is negative, the ECG is unremarkable, and the stress test comes back “normal.” The cardiologist reviews the angiogram: no obstructive coronary artery disease. The discharge summary reads “non-cardiac chest pain.” She is sent home again.

But the pain keeps coming back.

This scenario plays out thousands of times each year in the United States, and women are disproportionately on the receiving end of that “everything is fine” conclusion. The problem is that “no obstructive CAD” and “no cardiac disease” are not the same thing. For a substantial portion of women with recurrent chest pain, the underlying mechanism operates entirely outside the large coronary arteries that stress tests and angiograms are designed to evaluate.

The Clinical Trap: When Normal Tests Do Not Mean No Disease

Standard cardiac workup is built around a model of chest pain rooted in obstructive coronary artery disease: a plaque narrows a vessel, blood flow drops during exertion, and ischemia occurs. Exercise stress testing looks for ST changes that signal flow-limiting stenosis. Coronary angiography visualizes the major epicardial vessels.

Both of these tools are well-suited to a pattern of disease that tends to predominate in men. In women, particularly those under 65, chest pain more often arises from mechanisms that do not involve large-vessel obstruction at all. When the big arteries look clean, clinicians trained in an obstructive-disease framework can conclude the heart is fine. Evidence increasingly suggests otherwise.

The term that anchors this discussion is INOCA: Ischemia with Non-Obstructive Coronary Arteries. It is an umbrella designation that encompasses several distinct pathophysiologic processes, all of which can produce genuine myocardial ischemia and disabling chest pain in the presence of an angiographically normal or near-normal coronary tree. Estimates suggest INOCA affects somewhere between 3 and 4 million women in the United States, making it far from a rare edge case.

What INOCA Actually Includes

INOCA is not a single diagnosis but a category. Three main subtypes deserve attention in clinical practice.

Coronary microvascular dysfunction (CMD) refers to impairment of the small coronary vessels, typically less than 500 micrometers in diameter, that cannot be seen on conventional angiography. These vessels regulate myocardial blood flow through changes in tone and resistance. When they malfunction, the heart muscle receives inadequate perfusion during physiologic demand even when the major arteries are wide open. The symptom pattern can closely resemble classic angina, including exertional chest pressure and dyspnea, but the underlying anatomy will not reveal itself on a standard stress test.

Coronary vasospasm describes episodic contraction of one or more coronary arteries, transiently reducing or eliminating blood flow. Also called variant angina or Prinzmetal angina in its classic form, vasospasm tends to occur at rest, often at night or in the early morning, rather than with exertion. Some women experience both microvascular dysfunction and superimposed vasospasm, a mixed presentation that complicates diagnosis and treatment.

Microvascular spasm is a related phenomenon involving spasm at the microvascular rather than epicardial level. It can produce ischemia and chest pain without angiographically visible spasm in the large vessels.

The WISE Study and What It Proved

The Women’s Ischemia Syndrome Evaluation (WISE) study was a landmark investigation that fundamentally changed how cardiologists should interpret chest pain in women with non-obstructive CAD. Conducted at multiple centers and published across a series of papers beginning in the early 2000s, the WISE research followed women referred for coronary angiography who were found to have no obstructive disease.

The striking finding was this: these women were not protected. They had higher rates of adverse cardiovascular events, more hospitalizations, reduced quality of life, and measurable mortality differences compared to age-matched women without chest pain. The “normal angiogram” did not confer a reassuring prognosis. Bairey Merz and colleagues demonstrated that symptoms were not psychosomatic artifacts; they were markers of genuine cardiovascular pathology.

This evidence shifted the clinical conversation. A woman sent home with “non-cardiac chest pain” after a normal angiogram may actually have a condition that warrants further evaluation and active treatment, not reassurance and discharge.

Why Standard Stress Tests Miss Microvascular Disease

Understanding why the conventional stress test fails in CMD requires a brief look at what the test actually measures. Exercise or pharmacologic stress testing is designed to provoke flow-limiting ischemia in vessels with significant stenosis. When a major coronary artery is 70% or more occluded, demand-induced ischemia produces ECG changes or wall motion abnormalities that the test captures. The test is calibrated to detect obstruction.

Coronary microvascular dysfunction operates on a different physiologic axis. The problem is not a plaque narrowing a large vessel; it is a failure of the microvasculature to dilate appropriately in response to increased demand. The major coronary arteries remain patent and look unobstructed. Because there is no focal stenosis to provoke, the standard stress test cannot see the pathology. A woman with severe CMD may have a completely normal or equivocal stress test and still be experiencing genuine cardiac ischemia during her daily activities.

This mismatch between test design and pathophysiology is the core reason so many women receive falsely reassuring results.

Coronary Flow Reserve: The Measurement That Changes the Picture

Coronary flow reserve (CFR) is the ratio of maximal hyperemic coronary blood flow to resting coronary blood flow. In healthy coronary physiology, the vessels can dilate substantially in response to demand, achieving a flow reserve of 3.0 to 5.0 or higher. When CFR falls below 2.0, the evidence shows microvascular dysfunction is present.

CFR can be measured in two ways. Invasively, it requires a specialized Doppler wire placed in the coronary artery during catheterization, with adenosine given to achieve maximal hyperemia. Noninvasively, stress cardiac MRI and PET imaging with perfusion protocols can estimate myocardial blood flow reserve. Some centers also use stress echocardiography with Doppler for coronary flow velocity assessment in the left anterior descending territory.

CFR measurement is not yet routine in most cardiac catheterization laboratories, and it is rarely performed during a standard angiogram. This creates a gap: a woman with CMD has a “normal angiogram” because no one measured what was actually wrong.

Coronary Vasospasm: Diagnosis and Treatment

Coronary vasospasm presents differently from exertional angina. The pain typically comes at rest, often at night, and may last longer than classic angina. Some women describe it as waking from sleep with severe chest pressure that resolves after several minutes. Nitroglycerin often provides relief. The resting ECG during an episode may show transient ST elevation, but between episodes the tracing is completely normal.

The gold standard for diagnosing coronary vasospasm is acetylcholine provocation testing during cardiac catheterization. A small dose of acetylcholine is infused into the coronary artery; in a normal vessel, this produces vasodilation. In a vessel prone to spasm, acetylcholine triggers focal or diffuse spasm that is visible on angiography and may reproduce the patient’s symptoms. This test is performed at specialized centers, and availability varies considerably.

When vasospasm is confirmed, first-line treatment is calcium channel blockers. Amlodipine and diltiazem are most commonly used. Long-acting nitrates provide additional relief in some patients. One critical prescribing caution: beta-blockers can worsen coronary vasospasm by leaving alpha-adrenergic tone unopposed. In a woman with vasospastic angina who is started on a beta-blocker for another indication, symptom escalation may result. This interaction is frequently overlooked in general cardiology practice.

Cardiac MRI: The Imaging Tool Changing Diagnosis

Cardiac magnetic resonance imaging with perfusion protocols (stress CMR) has emerged as an important diagnostic tool for women with chest pain and non-obstructive coronary disease. Unlike stress echocardiography, which depends on wall motion abnormalities that may not develop with diffuse microvascular ischemia, CMR with gadolinium-based perfusion can visualize subendocardial perfusion defects that reflect microvascular insufficiency.

The subendocardium is the myocardial layer most vulnerable to ischemia because it lies farthest from the epicardial vessels. In CMD, perfusion defects often appear as diffuse or patchy subendocardial hypoperfusion rather than the focal wedge-shaped defects typical of obstructive disease. CMR can detect this pattern. It can also identify myocardial fibrosis on late gadolinium enhancement sequences, which may reflect prior microinfarction even in the absence of detectable troponin at the time of symptoms.

Some cardiologists now consider stress CMR the preferred noninvasive test for women with recurrent chest pain after a negative standard workup.

Sex Hormones and Microvascular Tone

Estrogen is a physiologic vasodilator. It acts on endothelial cells to promote nitric oxide production, which maintains vascular tone and microvascular reactivity. During the reproductive years, estrogen provides a degree of protection against both CMD and vasospasm. When estrogen levels fall at perimenopause and menopause, this protection is reduced.

This hormonal transition is clinically significant. Many women first present with exertional chest pain or rest chest pain in the perimenopausal years, even without traditional cardiovascular risk factors. The timeline of symptom onset, relative to menstrual cycle changes, can be an important diagnostic clue. Perimenopause is when INOCA often surfaces clinically, and cardiologists who are not looking for this pattern may attribute symptoms to anxiety, acid reflux, or musculoskeletal causes.

Hormone therapy for cardiovascular protection remains a nuanced and contested area, but the observation that estrogen withdrawal worsens microvascular reactivity is well-supported by physiologic evidence.

The Autoimmune Intersection

Women with autoimmune and inflammatory conditions carry a higher burden of microvascular cardiovascular disease than the general population. Rheumatoid arthritis, systemic lupus erythematosus, and antiphospholipid syndrome are all associated with CMD, accelerated atherosclerosis, and a propensity for coronary vasospasm.

In clinical practice, the autoimmune-cardiac connection is frequently missed. A woman with lupus who presents with chest pain may have her symptoms attributed to musculoskeletal pain or pleuritis, which are common in lupus. A woman with RA and chest pain may be told her joints are causing referred pain. While these explanations are sometimes correct, CMD and vasospasm are genuine differential diagnoses in this population that warrant cardiac evaluation when symptoms are recurrent or severe.

Inflammatory cytokines impair endothelial function, reduce nitric oxide bioavailability, and promote microvascular smooth muscle dysfunction. The same mechanisms that drive joint inflammation in RA also attack the coronary microvasculature. Some cardiologists advocate for earlier cardiac functional testing in women with inflammatory arthritis who develop any atypical cardiopulmonary symptoms.

Treatment Options for INOCA

The treatment landscape for INOCA is less well-developed than for obstructive CAD, and evidence for some interventions remains limited. Several approaches show promise.

Ranolazine is a sodium channel blocker originally approved for chronic angina in obstructive disease. Evidence from several smaller trials suggests benefit in microvascular angina, particularly in reducing anginal episodes and improving quality of life. The mechanism is thought to involve reduction of late sodium current, which reduces myocardial oxygen demand and may improve subendocardial perfusion.

ACE inhibitors improve endothelial function through multiple mechanisms, including reduction of angiotensin II-mediated vasoconstriction. Some cardiologists use ACE inhibitors as part of the treatment strategy for CMD, particularly in women with hypertension or diabetes as comorbidities.

Statins have pleiotropic effects beyond lipid lowering, including improved endothelial function and reduced vascular inflammation. The evidence shows statins may improve coronary flow reserve in women with CMD, even in those without significantly elevated LDL.

Ivabradine, which reduces heart rate by blocking the If current in the sinoatrial node, may help some women with microvascular angina by prolonging diastole and improving coronary perfusion time.

For vasospasm, the approach differs. Calcium channel blockers are the cornerstone. Long-acting nitrates provide additional symptom control. Beta-blockers should be used cautiously and may need to be avoided entirely if vasospasm is the dominant mechanism.

The MINOCA Overlap

MINOCA stands for Myocardial Infarction with Non-Obstructive Coronary Arteries. It represents the higher-acuity end of the INOCA spectrum, where an actual infarction occurs in the absence of flow-limiting plaque. MINOCA accounts for approximately 5 to 10 percent of all myocardial infarctions and is more common in women than men.

Some presentations of recurrent chest pain with “normal” tests may actually represent subclinical MINOCA events. Standard troponin assays may not detect small microinfarctions. High-sensitivity troponin, combined with CMR late gadolinium enhancement imaging, can identify myocardial injury that would be missed by routine testing. Women who present multiple times with chest pain and normal routine workup deserve consideration of high-sensitivity troponin and CMR if the symptom pattern is consistent with ischemia.

This distinction matters clinically. MINOCA has a prognosis that is meaningfully worse than INOCA without infarction. Identifying it changes the urgency and intensity of secondary prevention efforts.

What Women Should Know About Next Steps

A woman who has had two or more unexplained episodes of chest pain with negative standard workup has not reached the end of her cardiac evaluation. She is at the beginning of a more specialized diagnostic pathway.

Referral to a center with expertise in CMD and vasospasm is appropriate. These centers can perform coronary reactivity testing (CRT) during catheterization, which includes both CFR measurement and acetylcholine provocation for vasospasm. The results directly inform treatment. Without this testing, treatment is empirical rather than mechanism-targeted.

Advocacy matters here. Women who have been told their heart is fine but continue to have symptoms should know that additional testing exists and that their symptoms are not imaginary. Cardiologists who specialize in INOCA exist in academic and quaternary care settings. The conversation is worth having.

The dismissal of recurrent chest pain in women with normal standard tests is not a harmless error. The WISE data and subsequent research are clear: these women have real cardiovascular pathology, real adverse outcomes, and real need for diagnosis and treatment. The test being normal is not the end of the story. It is a signal that the right tests have not yet been performed.

A Note on Language and Advocacy

One practical recommendation for women navigating this diagnostic gap: ask specifically whether coronary microvascular dysfunction or vasospasm has been considered, and ask whether coronary flow reserve has been measured. These are not fringe concepts; they appear in current guidelines from the American Heart Association and the European Society of Cardiology. If the answer is that these assessments are unavailable at a given center, a second opinion at a specialist referral center is a reasonable and appropriate request.

Cardiovascular medicine has made significant progress in recognizing INOCA as a genuine clinical entity rather than a wastebasket diagnosis for unexplained symptoms. The goal now is ensuring that this recognition reaches every clinical encounter where a woman sits in an examination room wondering why she keeps having chest pain when “nothing is wrong.”

The Women’s Signal Check is fifteen questions mapping the female cardiovascular risk pattern, including reproductive history, microvascular signals, and the factors standard risk calculators do not capture. It produces a specific starting point for your next clinical conversation.